Accuray | ARAY - Cash And Equivalent


Accuray reported $41.29M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Accuray USD 41.29M 22.05M Dec/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Artivion USD 55.76M 9.14M Mar/2026
AtriCure USD 146.16M 21.26M Mar/2026
Boston Scientific USD 1.45B 512M Mar/2026
Edwards Lifesciences USD 2.4B 538M Mar/2026
Inogen USD 106.48M 2.79M Sep/2025
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Orthofix International USD 120.28M 38.25M Mar/2026
Surmodics USD 36.11M 11.81M Sep/2024
Tandem Diabetes Care USD 179.32M 88.69M Mar/2026
Trinity Biotech USD 1.34M 3.83M Sep/2025